When is a diagnostic reagent classified under HTS 3822 versus Chapter 30?

Apply the patient-administration test. Heading 3822 covers prepared diagnostic and laboratory reagents that do their work in vitro, on a specimen in a lab or on a test device, and its text excludes headings 3002 and 3006. Diagnostic reagents designed to be administered to the patient, like opacifying preparations for radiological examination, belong to subheading 3006.30, and immunological products such as antisera fall under 3002 on their own composition. GingerControl's classifier runs exactly this exclusion sequence with the reasoning documented.

Why did CBP split one reagent kit across two headings in NY N256882?

In NY N256882 (February 5, 2015), an iron-assay kit imported in bulk from Canada came as two bottles: CBP classified the color reagent, the prepared diagnostic component, under 3822 at a free rate, and the dissociating reagent under 3824 as a general chemical preparation at 5 percent. The lesson is that kit components imported in bulk are classified on their own merits, and the duty difference between 3822 and 3824 can be the whole margin on a reagent line.

How are certified reference materials classified?

Certified reference materials are named in heading 3822's own text, and Chapter 38's notes give the heading classification priority for qualifying CRMs, which spares importers the fight over the underlying chemistry. The documentation burden shifts instead to proving CRM status, the certificate stating certified values and traceability. Get that file wrong and the fallback is classification on composition, which usually means a worse rate.

What documentation decides a reagent classification?

Three documents do most of the work: the product insert or IFU showing in-vitro versus patient-administered use, the composition breakdown showing whether the product is a prepared mixture or a separate chemically defined compound that belongs in Chapter 29, and for kits, the packaging configuration at import. Classification fails upstream when those documents are missing, which is a supplier data problem before it is a tariff problem.

HTS 3822 Diagnostic Reagents: Where Heading 3822 Ends and Chapter 30 Begins

GingerControl walks through classifying diagnostic reagents under HTS 3822: the patient-administration test, the NY N256882 kit-split lesson, and a four-step decision sequence.

Chen Cui· Co-Founder of GingerControl· July 26, 2026

Connect with me on LinkedIn! I want to help you :)

Reviewed by: Michael Weick, LCB / CCS

Customs compliance manager with 42 years of experience (ex Subaru of America, Merck, and Motorola).

TL;DR

Heading 3822 covers prepared diagnostic and laboratory reagents used in vitro, and its own text excludes headings 3002 and 3006, so the boundary question is answerable in one test: reagents designed to be administered to the patient belong to Chapter 30, reagents that do their work in the lab stay in 3822, and NY N256882 shows CBP splitting a single two-bottle kit across 3822 and 3824 because one bottle stopped qualifying as a prepared diagnostic reagent.

When is a reagent heading 3822, and when is it Chapter 30?

Heading 3822 covers diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents, whether or not in kits, other than those of heading 3002 or 3006, plus certified reference materials. That exclusion in the heading text is the whole boundary: before 3822 can apply, you must clear Chapter 30, and the clearing question is one test.

The Patient-Administration Test: a diagnostic reagent designed to be administered to the patient, swallowed, injected, or otherwise introduced into the body, such as an opacifying preparation for radiological examination, classifies in subheading 3006.30 under Chapter 30. A reagent that does its diagnostic work outside the body, on a blood draw, a swab, a slide, or a lateral-flow device, stays in heading 3822. Immunological products like antisera and blood fractions classify in 3002 on what they are, regardless of lab use.

Last updated: July 26, 2026

What NY N256882 teaches about reagent kits

In NY N256882 (February 5, 2015), CBP classified an iron-assay reagent set imported in bulk from Canada, two components sold to work together. The holding split them: the color reagent, the component that actually performs the diagnostic reaction, went to heading 3822 at a free rate of duty, while the companion dissociating reagent went to heading 3824 as a general chemical preparation, dutiable at 5 percent under the rates then in force.

Three lessons for anyone importing reagent lines:

Bulk kills the kit. Components imported in bulk are classified individually; the retail-set analysis that might have carried both bottles into 3822 only becomes available when goods arrive put up together for retail sale.
"Prepared diagnostic reagent" is a functional standard. The bottle that develops the diagnostic signal earned 3822; the helper chemistry did not.
The spread is the stakes. Free versus dutiable on adjacent bottles in the same box is exactly the kind of line-level spread a duty audit later finds, in either direction.

A four-step decision sequence for reagent classification

Chapter 30 first. Administered to the patient? Then 3006.30 territory. An immunological product or blood fraction? Then 3002, full stop, 3822's own text yields.
Chapter 29 check. A separate chemically defined compound, a pure chemical merely used in a lab, generally belongs in Chapter 29, not 3822. "Prepared" in 3822 means a preparation: mixed, on a backing, or put up for diagnostic use.
CRM claim. If the product is a certified reference material with the certificate to prove it, heading 3822 takes priority under Chapter 38's notes, document the certified values and traceability.
Kit configuration. Components in bulk classify separately, per N256882; genuine retail sets trigger GRI 3(b) essential-character analysis, and the answer can differ shipment by shipment if your packaging does.

This is GRI 1 doing most of the work, heading texts and chapter notes, before GRI 3 ever enters. GingerControl's HTS Classification Researcher runs this same sequence, candidate headings, the 3002/3006 exclusions, kit analysis, with CROSS precedent read during classification rather than pasted on after, and every step documented for review. Run a reagent through it.

References

[REF 1] U.S. Customs and Border Protection, ruling NY N256882 Data cited: kit-split holding, 3822 free rate vs 3824 dutiable component, February 5, 2015 Source: CROSS ruling N256882 Published: February 5, 2015

[REF 2] Harmonized Tariff Schedule of the United States, heading 3822 and Chapter 30 Data cited: heading text exclusions for 3002/3006, subheading 3006.30, certified reference materials Source: USITC HTS

Written by

Chen Cui

Co-Founder of GingerControl

Building scalable AI and automated workflows for trade compliance teams.

LinkedIn Profile

Frequently Asked Questions

When is a diagnostic reagent classified under HTS 3822 versus Chapter 30?: Apply the patient-administration test. Heading 3822 covers prepared diagnostic and laboratory reagents that do their work in vitro, on a specimen in a lab or on a test device, and its text excludes headings 3002 and 3006. Diagnostic reagents designed to be administered to the patient, like opacifying preparations for radiological examination, belong to subheading 3006.30, and immunological products such as antisera fall under 3002 on their own composition. GingerControl's classifier runs exactly this exclusion sequence with the reasoning documented.
Why did CBP split one reagent kit across two headings in NY N256882?: In NY N256882 (February 5, 2015), an iron-assay kit imported in bulk from Canada came as two bottles: CBP classified the color reagent, the prepared diagnostic component, under 3822 at a free rate, and the dissociating reagent under 3824 as a general chemical preparation at 5 percent. The lesson is that kit components imported in bulk are classified on their own merits, and the duty difference between 3822 and 3824 can be the whole margin on a reagent line.
How are certified reference materials classified?: Certified reference materials are named in heading 3822's own text, and Chapter 38's notes give the heading classification priority for qualifying CRMs, which spares importers the fight over the underlying chemistry. The documentation burden shifts instead to proving CRM status, the certificate stating certified values and traceability. Get that file wrong and the fallback is classification on composition, which usually means a worse rate.
What documentation decides a reagent classification?: Three documents do most of the work: the product insert or IFU showing in-vitro versus patient-administered use, the composition breakdown showing whether the product is a prepared mixture or a separate chemically defined compound that belongs in Chapter 29, and for kits, the packaging configuration at import. Classification fails upstream when those documents are missing, which is a supplier data problem before it is a tariff problem.

Does Moving Your Sourcing Actually Cut Your Tariff Bill? Which 2026 Duties Follow Origin — and Which Follow the Metal

Moving sourcing out of China cuts the origin-based tariff layers (Section 301, base MFN) but not Section 232, which follows where the metal was melted — not where the article was assembled. Here's how to tell which of your duty is escapable before you relocate.

July 25, 2026

AI Data-Center Import Duty in 2026: The Tariff Is in the Power and Cooling, Not the Chips

Most GPUs enter duty-free — the real import duty on an AI data-center buildout is on the power and cooling gear. Here's the 2026 Section 232 stack on transformers, switchgear, and cooling — including the full-value metals duty that turns a Free-rated transformer into a double-digit landed cost.